BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Monash Innovation Labs And Agilent Technologies Australia Deepen Applied Research Partnership

03 February, 2026 | News

AstraZeneca Commits $15 Billion Investment To Expand R&D And Manufacturing Footprint In China Through 2030

03 February, 2026 | News

MicuRx Pharmaceuticals Receives FDA IND Clearance For MRX 5 In Mycobacterium abscessus Pulmonary Disease

03 February, 2026 | News

Frontage Laboratories Expands Early Phase Clinical Research Capabilities Across The United States And China

03 February, 2026 | News

Ascletis Pharma Reports Positive Phase III Safety Results For Denifanstat In Moderate To Severe Acne

03 February, 2026 | News

Closing Asia’s Cancer Evidence Gap Through Translational Science And Policy Leadership

In this BioPharma APAC interview, Dr Yun Yen, Program Committee Chair for the 2026 ASCO Breakthrough meeting, shares a candid translational medicine perspective on why global oncology research o...

Lab

02 February, 2026 | Monday | Expert Insight

Turning Frontline Reality Into Policy Action For Cancer Care In Asia

Drawing on her frontline clinical experience in Malaysia, Prof Dr Wan Zamaniah, Consultant Clinical Oncologist, University Malaya Medical Centre offers a clear view of the structural barriers tha...

BioTech

02 February, 2026 | Monday | News

China Originated Innovation Is Rising. Global Expectations Are Rising Even Faster.

The momentum is real—and so is the level of scrutiny. As more programs move beyond regional boundaries, expectations from global biopharma companies have become sharper and more consistent, particularly a...

Contract Services

02 February, 2026 | Monday | News

Fidēs Launches Science Led Imaging CRO Focused On Early Phase Clinical Decision Making

Fidēs announced its launch as a new imaging contract research organization (iCRO) designed specifically for early-phase clinical development, where imaging decisions have the greatest impact on scientific direc...

Consumer Health

02 February, 2026 | Monday | News

China Approves World First cAMP Biased GLP One Receptor Agonist For Type Two Diabetes

Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced that China's National Medical Products A...

White Paper

05 January, 2026 | Monday | News

GHIT Fund Commits JPY 1.39 Billion To Back Six R&D Programmes Across Malaria, Tuberculosis And Neglected Tropical Diseases

Biopharma APAC Infomercial

Monash Innovation Labs And Agilent Technologies Australia Deepen Applied Research Partnership

AstraZeneca Commits $15 Billion Investment To Expand R&D And Manufacturing Footprint In China Through 2030

MicuRx Pharmaceuticals Receives FDA IND Clearance For MRX 5 In Mycobacterium abscessus Pulmonary Disease

Frontage Laboratories Expands Early Phase Clinical Research Capabilities Across The United States And China

Ascletis Pharma Reports Positive Phase III Safety Results For Denifanstat In Moderate To Severe Acne

Closing Asia’s Cancer Evidence Gap Through Translational Science And Policy Leadership

Turning Frontline Reality Into Policy Action For Cancer Care In Asia

China Originated Innovation Is Rising. Global Expectations Are Rising Even Faster.

Fidēs Launches Science Led Imaging CRO Focused On Early Phase Clinical Decision Making

China Approves World First cAMP Biased GLP One Receptor Agonist For Type Two Diabetes

26 Key Trends Shaping Biotech And Life Sciences In 2026

Animate Biosciences Delivers Ai Designed Peptides That Match Standard Of Care In Pulmonary Fibrosis Model

APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage

GHIT Fund Commits JPY 1.39 Billion To Back Six R&D Programmes Across Malaria, Tuberculosis And Neglected Tropical Diseases

Stay Connected